Norfolk, Virginia, October 12, 2023–(BUSINESS WIRE)–ReAlta Life Sciences (“ReAlta”), Inc., a mid-stage clinical biotechnology company focused on harnessing the power of the immune system to address life-threatening diseases, is pleased to welcome Senator Mark R. Warner (D-Va) conducted an in-depth interview with the ReAlta management team, ReAlta board members and local investors on October 2, 2023.
This press release uses multimedia. View the full version here: https://www.businesswire.com/news/home/20231012073021/en/
senator. Mark Warner (D-Va.) with ReAlta CEO Dr. Ulrich Thienel, Chairman of the Board Edward Heidt, Jr., Chief Marketing Officer Dr. Kenji Cunnion, CSO Dr. Neel Krishna, and ReAlta employees. (Photo: Business Wire)
During the visit, Senator Warner had active discussions with members of ReAlta’s management team regarding the company’s ongoing clinical trials and plans to develop commercial applications of its EPICC drug platform, which will enable patients with acute inflammatory diseases such as hypoxic-ischemic encephalopathy. Disease patients benefit. HIE), graft-versus-host disease (GvHD), and acute pulmonary exacerbation. The senator, who chairs the Senate Select Committee on Intelligence, also learned about other research initiatives ReAlta is pursuing to treat life-threatening inflammatory diseases such as acute respiratory distress syndrome (ARDS), acute radiation syndrome, caused by the pandemic virus. and the Department of Defense, BARDA, and other federal agencies interested in sepsis.
“We are honored to host Senator Warner and thank him for his interest in our treatment of patients with HIE and GvHD, as well as those with a variety of lung diseases,” said Ulrich Thienel, MD, PhD, CEO of ReAlta Life Sciences. With the potential applications of our EPICC platform to treat the medical threats our military personnel in the field and our civilians face in the wake of another pandemic, Senator Warner’s visit highlights the potential that companies like ReAlta can The vital role that healthcare infrastructure plays in our national economy and society.”
“ReAlta is at the forefront of research in areas ranging from COVID-19 to birth asphyxia,” said Mark R. Warner. “I’m proud to have such a dynamic and nimble company in Virginia, and I look forward to seeing their work continue to break ground.” The Boundaries of Treating Acute Inflammation and Rare Diseases.”
ReAlta thanks Senator Warner for his visit and his continued support of biotech innovation in Virginia. The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a mid-stage clinical biotechnology company focused on harnessing the power of the immune system to address life-threatening acute inflammatory and rare diseases. The company’s EPICC peptide is based on research into the human astrovirus HAstV-1, which causes a unique among viruses, non-inflammatory, self-limiting gastroenteritis by suppressing components of the innate immune system. ReAlta’s therapeutic peptides exploit these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute graft-versus-host disease and has received IND approval, Orphan Drug designation, and Fast Track specified. The FDA and European Medicines Agency granted orphan drug designation for the treatment of hypoxic-ischemic encephalopathy (HIE). The company was founded in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231012073021/en/
Contact information
Media and investor contact information:
John Rickman
CFO
jrickman@realtals.com